Pharmaceutical intermediates
Ribociclib Succinate Intermediates
2 pharmaceutical intermediates for Ribociclib Succinate. Indication: Breast cancer.
About Ribociclib Succinate
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Breast cancer
- Approved Date
- 03/13/2017
- DS/DP
- 06/17/2028
Available intermediates
2 intermediates currently listed for Ribociclib Succinate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid | 1211443-58-1 | / | / |
| 2-Chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide | 1211443-61-6 | / | / |
Other programs under R
Building toward Ribociclib Succinate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →